Search

621 Result(s)
Sort by

commitments to sustainable development

commitments to sustainable development

On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
The impact of A Life in a Day of a patient

The impact of A Life in a Day of a patient

A Life in a Day disease simulations are opening our eyes to the patient experience, exposing a surprising knowledge gap and driving change.
FDA-Fast-Track-chronic-kidney-disease

FDA-Fast-Track-chronic-kidney-disease

FDA grants Fast Track designation for the treatment of chronic kidney disease, underscoring urgent need for new treatments for people living with the condition
Phase II trials for patients with bronchiectasis

Phase II trials for patients with bronchiectasis

Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
Soaring to save lives

Soaring to save lives

Tackling health disparities through drone delivery of vaccines animals and livestock living in underserved communities
Vetera

Vetera

For vaccination of healthy horses as an aid in the prevention of diseases caused by the included antigens (US and Canada only).
NexGard Spectra

NexGard Spectra

Prevents heartworm disease and treats and controls hookworm, roundworm, whipworm, and lungworm infestations in dogs and puppies.
survodutide top-line results MASH fibrosis

survodutide top-line results MASH fibrosis

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Our-position

Our-position

Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
emperor-preserved-kidney-subanalysis

emperor-preserved-kidney-subanalysis

New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
New data for nintedanib in children with fibrosing ILD

New data for nintedanib in children with fibrosing ILD

InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
Prascend

Prascend

Symptomatic treatment of clinical signs associated with pituitary pars intermedia dysfunction (PPID; also known as equine Cushing’s disease).
Retinal Health: Meet the Scientists

Retinal Health: Meet the Scientists

We aim to prevent, treat, and restore vision loss. Delve behind the lab to see our scientists spearheading research to address retinopathies.
Behind the Lab

Behind the Lab

Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
Prevexxion™ RN

Prevexxion™ RN

The vaccine is recommended for in ovo vaccination of 18 to 19-day-old embryonated chicken eggs to protect against the very virulent Marek’s disease.
Heartgard Plus

Heartgard Plus

Prevents canine heartworm disease by eliminating the tissue stage of heartworm larvae for a month after infection, also treatment and control of roundworms and hookworms.